Pulse Biosciences enrolls first patients in thyroid cancer feasibility study of Vybrance nsPFA system

PULSE BIOSCIENCES, INC.

First-in-human cases completed at Sarasota Memorial and MD Anderson for T1N0M0 papillary thyroid microcarcinoma.
Study is a multicenter, prospective feasibility trial; 30 patients planned across two sites.
System has FDA 510(k) clearance for soft tissue ablation; study runs under IDE for thyroid indications.
Primary endpoints: safety and effectiveness of nsPFA in treating tumors <1.5 cm.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.